Sai Parenteral's Shares Open at 2% Premium Over IPO Price on NSE: Investment Insights

Sai Parenteral Sees Strong Listing on National Stock Exchange

Sai Parenteral's shares made a strong debut on the National Stock Exchange (NSE) on Thursday, listing at more than 2 percent premium over its initial public offer (IPO) price. The company's diversified pharmaceutical formulation business saw a robust response from institutional investors, leading to the issue being fully subscribed on the closing day of bidding between March 24-27 in the primary market.

The listing price of Sai Parenteral's shares on the NSE was Rs 400 per share, representing a 2.04 percent premium over the IPO price. The Rs 409-crore issue was offered to investors at a price band of Rs 372-392 per share. This strong performance in the primary market bodes well for the company's future growth prospects.

On the Bombay Stock Exchange (BSE), the shares of Sai Parenteral were listed at Rs 405 per share, a premium of 3.31 percent. The company's market capitalization post listing of shares stood at Rs 1,779.76-crore. This significant increase in market capitalization highlights the confidence investors have in the company's business model.

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

Sai Parenteral's market debut was better than the expectations in the grey market, which had anticipated a muted listing for the shares of the company. This strong listing performance is a testament to the company's attractive business proposition and its ability to tap into the growing demand for pharmaceutical formulation services.